Linalog Tablet contains Alpha Ketoanalogue (NA), a specialized nutritional supplement primarily used in the management of chronic kidney disease (CKD). It serves as a precursor to essential amino acids, aiding in the reduction of nitrogenous waste accumulation and minimizing the progression of uremia in patients with impaired renal function. By providing ketoanalogues of essential amino acids, Linalog Tablet supports protein synthesis while allowing for a low-protein diet, which is often recommended to reduce renal workload. This therapeutic approach helps in maintaining nutritional status and delaying the need for dialysis. Linalog is indicated as an adjunct to dietary protein restriction in patients with moderate to severe renal insufficiency. The tablet should be administered under medical supervision, with dosage tailored according to the severity of renal impairment and dietary protein intake. Commonly, it is prescribed alongside other supportive measures including phosphate binders and antihypertensive agents. Linalog Tablet is contraindicated in patients with hypersensitivity to its components and should be used cautiously in those with hepatic dysfunction. Regular monitoring of renal function, serum electrolytes, and nutritional parameters is essential during therapy. Adverse effects are uncommon but may include gastrointestinal discomfort. Linalog Tablet represents an important modality in conservative management strategies aimed at improving quality of life in CKD patients.